drugset / Trial / NCT04952571
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.
Timeline
- Start
- 2021-06-27
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Outcome
Outcome not reported
Stopped (Business): “Lack of funds”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |